Los puntos clave no están disponibles para este artículo en este momento.
Among patients with hemophilia A or B with inhibitors, the annualized bleeding rate was lower with concizumab prophylaxis than with no prophylaxis. (Funded by Novo Nordisk; explorer7 ClinicalTrials.gov number, NCT04083781.).
Matsushita et al. (Wed,) studied this question.